Forbes: Negative clinical trial results could end the wide use of drugs to prevent heart attacks, cardiologist says

A story on Forbes' The Science Business blog reports a government study of the best-selling heart drug TriCor will be conducted to determine its effectiveness in reducing heart attacks and deaths in diabetics, and quotes William Boden, professor of medicine and public health, who said if the new trial comes up negative, "it could be the end" of wide use of the drug.